-
CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck
Monday, August 8, 2016 - 10:12am | 409Read More...Bristol-Myers Squibb Co (NYSE: BMY) announced that the CheckMate-026 [CM-026] Study for Opdivo in non-small cell lung cancer [NSCLC] had missed its primary endpoint. Terming the announcement as “stunning,” Credit Suisse’s Vamil Divan said in a report that CM-026 was being...
-
Allergan's Pipeline Is 'Underappreciated'
Monday, July 25, 2016 - 8:58am | 316Read More...Allergan plc (NYSE: AGN) has a “broad and underappreciated” pipeline, which should boost the company’s already robust base business, Credit Suisse’s Vamil Divan said in a report. He initiated coverage of the company with an Outperform rating and a price target of $327....
-
Esperion Therapeutics Downgraded On Regulatory Concerns By Credit Suisse
Wednesday, June 29, 2016 - 9:44am | 259Read More...Credit Suisse’s Vamil Divan expressed concern regarding the outlook for bempedoic acid in the U.S. market, following the update provided by Esperion Therapeutics Inc (NASDAQ: ESPR) regarding the its development plans for the product. Divan downgraded the rating on the company from Neutral...
-
Portola Pharma Risk-Reward Is Questionable
Tuesday, May 31, 2016 - 10:37am | 264Read More...Credit Suisse has downgraded Portola Pharmaceuticals Inc (NASDAQ: PTLA) to Neutral from Outperform on balanced risk/reward following the recovery in shares since late March. The brokerage also cut its price target by $3 to $30 on "more conservative assumptions around the uptake of Andexanet Alfa...
-
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers
Monday, April 25, 2016 - 1:57pm | 335Read More...The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...
-
Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook
Saturday, December 19, 2015 - 6:08pm | 504Read More...Vamil Divan of Credit Suisse offered his 2016 outlook for large-cap U.S. pharmaceuticals. Divan noted that sector-wide challenges seen in 2015 will remain and limit the sector's ability to outperform in 2016. The analyst named Eli Lilly and Co (NYSE: LLY), Pfizer Inc. (NYSE: PFE) and...
-
Why These Two Firms Downgraded ZS Pharma Stock
Monday, November 9, 2015 - 9:38am | 525Read More...ZS Pharma Inc (NASDAQ: ZSPH) shares have gained 114 percent year-to-date, and are trading close to the high-end of their 52-week range of $34.35 - $89.40. Credit Suisse’s Vamil Divan and Morgan Stanley’s Andrew S Berens have downgraded their ratings on the company. The...
-
How Allergan Could Be Pfizer's Rocket Ship
Thursday, October 29, 2015 - 12:19pm | 583Read More...Pfizer Inc. (NYSE: PFE) confirmed media reports that the company is in talks with Allergan PLC (NYSE: AGN) over a potential business combination transaction. Pfizer said it is in "preliminary friendly discussions" with Allergan, but offered no assurances that the conversations will...
-
Edge Therapeutics Initiated Outperform At Credit Suisse
Monday, October 26, 2015 - 11:17am | 222Read More...Shares of Edge Therapeutics Inc (NASDAQ: EDGE) have appreciated 3 percent year-to-date, although the share price has been very volatile through 2015. Vamil Divan of Credit Suisse has initiated coverage of the company with an Outperform rating and price target $29. Divan views the company...
-
Johnson & Johnson Sales Fall: What The Street Is Saying Now
Tuesday, October 13, 2015 - 12:25pm | 431Read More...Johnson & Johnson (NYSE: JNJ)’s Q3 revenue came up short of consensus estimates, but the company managed a beat on its EPS number. The company also announced an additional $10 billion in share buybacks. Wall Street firms and the market seem split on how to interpret the company’s...
-
Aimmune An Opportunity For Unmet Needs
Monday, August 31, 2015 - 11:01am | 265Read More...Aimmune Therapeutics Inc (NASDAQ: AIMT) shares have been declining this month, after peaking at $26.63 on August 14. Credit Suisse’s Vamil Divan initiated coverage of the company with an Outperform rating and a price target of $44. Divan believes there is opportunity for upside from...
-
Why Does Credit Suisse Like Portola Pharma?
Wednesday, June 24, 2015 - 1:59pm | 370Read More...In a report issued Wednesday, Credit Suisse analysts Vamil Divan and Muriel Chen assumed coverage of Portola Pharmaceuticals Inc (NASDAQ: PTLA) with an Outperform rating and $51 target price, on the back of an appealing emerging cardiovascular franchise. The analysts see the company as a high-...
-
This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says
Monday, June 8, 2015 - 2:03pm | 298Read More...Eli Lilly and Co (NYSE: LLY) will release key data Thursday on its prospective autoimmune drug baricitinib that an analyst said will become a market leader with 2023 sales of $2.5 billion. Credit Suisse's Vamil Divan boosted his price target on Lilly about 4 percent Monday to $75. Divan...
-
UPDATE: Credit Suisse Downgrades Allergan
Tuesday, June 3, 2014 - 11:00am | 133Read More...Allergan (NYSE: AGN) on Tuesday was downgraded to Neutral from Outperform by Credit Suisse due to a balanced risk/reward profile following the latest takeover offer from Valeant Pharmaceuticals International. Stating that the latest Valeant Pharmaceuticals offer warrants consideration, Credit...
-
UPDATE: Credit Suisse Upgrades Forest Laboratories on Business Improvements, Opportunities
Friday, January 17, 2014 - 10:16am | 179Read More...In a report published Thursday, Credit Suisse analyst Vamil Divan upgraded Forest Laboratories (NYSE: FRX) from Neutral to Outperform and raised the price target from $60.00 to $85.00 due to the company's business improvements and opportunity. Divan noted his increased confidence in the potential...
